Literature DB >> 20805472

Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.

Anne W Rimoin1, Prime M Mulembakani, Sara C Johnston, James O Lloyd Smith, Neville K Kisalu, Timothee L Kinkela, Seth Blumberg, Henri A Thomassen, Brian L Pike, Joseph N Fair, Nathan D Wolfe, Robert L Shongo, Barney S Graham, Pierre Formenty, Emile Okitolonda, Lisa E Hensley, Hermann Meyer, Linda L Wright, Jean-Jacques Muyembe.   

Abstract

Studies on the burden of human monkeypox in the Democratic Republic of the Congo (DRC) were last conducted from 1981 to 1986. Since then, the population that is immunologically naïve to orthopoxviruses has increased significantly due to cessation of mass smallpox vaccination campaigns. To assess the current risk of infection, we analyzed human monkeypox incidence trends in a monkeypox-enzootic region. Active, population-based surveillance was conducted in nine health zones in central DRC. Epidemiologic data and biological samples were obtained from suspected cases. Cumulative incidence (per 10,000 population) and major determinants of infection were compared with data from active surveillance in similar regions from 1981 to 1986. Between November 2005 and November 2007, 760 laboratory-confirmed human monkeypox cases were identified in participating health zones. The average annual cumulative incidence across zones was 5.53 per 10,000 (2.18-14.42). Factors associated with increased risk of infection included: living in forested areas, male gender, age < 15, and no prior smallpox vaccination. Vaccinated persons had a 5.2-fold lower risk of monkeypox than unvaccinated persons (0.78 vs. 4.05 per 10,000). Comparison of active surveillance data in the same health zone from the 1980s (0.72 per 10,000) and 2006-07 (14.42 per 10,000) suggests a 20-fold increase in human monkeypox incidence. Thirty years after mass smallpox vaccination campaigns ceased, human monkeypox incidence has dramatically increased in rural DRC. Improved surveillance and epidemiological analysis is needed to better assess the public health burden and develop strategies for reducing the risk of wider spread of infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805472      PMCID: PMC2941342          DOI: 10.1073/pnas.1005769107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

2.  Discovery of monkeypox in Sudan.

Authors:  Inger K Damon; Cathy E Roth; Vipul Chowdhary
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

3.  Human infection with monkeypox virus: laboratory investigation of six cases in West Africa.

Authors:  B Lourie; P G Bingham; H H Evans; S O Foster; J H Nakano; K L Herrmann
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

4.  The detection of monkeypox in humans in the Western Hemisphere.

Authors:  Kurt D Reed; John W Melski; Mary Beth Graham; Russell L Regnery; Mark J Sotir; Mark V Wegner; James J Kazmierczak; Erik J Stratman; Yu Li; Janet A Fairley; Geoffrey R Swain; Victoria A Olson; Elizabeth K Sargent; Sue C Kehl; Michael A Frace; Richard Kline; Seth L Foldy; Jeffrey P Davis; Inger K Damon
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

5.  Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus.

Authors:  Victoria A Olson; Thomas Laue; Miriam T Laker; Igor V Babkin; Christian Drosten; Sergei N Shchelkunov; Matthias Niedrig; Inger K Damon; Hermann Meyer
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

6.  Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler.

Authors:  David A Kulesh; Bonnie M Loveless; David Norwood; Jeffrey Garrison; Chris A Whitehouse; Chris Hartmann; Eric Mucker; David Miller; Leonard P Wasieloski; John Huggins; Gregory Huhn; Lori L Miser; Carroll Imig; Mark Martinez; Tom Larsen; Cynthia A Rossi; George V Ludwig
Journal:  Lab Invest       Date:  2004-09       Impact factor: 5.662

7.  Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms.

Authors:  David A Kulesh; Robert O Baker; Bonnie M Loveless; David Norwood; Susan H Zwiers; Eric Mucker; Chris Hartmann; Rafael Herrera; David Miller; Deanna Christensen; Leonard P Wasieloski; John Huggins; Peter B Jahrling
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

8.  Smallpox and monkeypox in non-human primates.

Authors:  I Arita; D A Henderson
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

9.  Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.

Authors:  Y J Hutin; R J Williams; P Malfait; R Pebody; V N Loparev; S L Ropp; M Rodriguez; J C Knight; F K Tshioko; A S Khan; M V Szczeniowski; J J Esposito
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

Review 10.  LC16m8: an attenuated smallpox vaccine.

Authors:  Julie Kenner; Fiona Cameron; Cyril Empig; David V Jobes; Marc Gurwith
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

View more
  189 in total

1.  Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

Authors:  M S Keckler; D S Carroll; N F Gallardo-Romero; R R Lash; J S Salzer; S L Weiss; N Patel; C J Clemmons; S K Smith; C L Hutson; K L Karem; I K Damon
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

4.  Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo.

Authors:  Andrea M McCollum; Yoshinori Nakazawa; Guy Mutombo Ndongala; Elisabeth Pukuta; Stomy Karhemere; Robert Shongo Lushima; Benoit Kebela Ilunga; Joelle Kabamba; Kimberly Wilkins; Jinxin Gao; Yu Li; Ginny Emerson; Inger K Damon; Darin S Carroll; Mary G Reynolds; Jean Malekani; Jean-Jacques Muyembe Tamfum
Journal:  Am J Trop Med Hyg       Date:  2015-08-17       Impact factor: 2.345

Review 5.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

6.  Comparing methods for estimating R0 from the size distribution of subcritical transmission chains.

Authors:  S Blumberg; J O Lloyd-Smith
Journal:  Epidemics       Date:  2013-06-03       Impact factor: 4.396

7.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

8.  Vacated niches, competitive release and the community ecology of pathogen eradication.

Authors:  James O Lloyd-Smith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

9.  Economic considerations for the eradication endgame.

Authors:  Scott Barrett
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

10.  Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.

Authors:  Graham J Hatch; Victoria A Graham; Kevin R Bewley; Julia A Tree; Mike Dennis; Irene Taylor; Simon G P Funnell; Simon R Bate; Kimberley Steeds; Thomas Tipton; Thomas Bean; Laura Hudson; Deborah J Atkinson; Gemma McLuckie; Melanie Charlwood; Allen D G Roberts; Julia Vipond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.